Antisense-mediated angiotensinogen inhibition slows polycystic kidney disease in mice with a targeted mutation in Pkd2

American Journal of Physiology - Renal Physiology

Volumn 308, Issue 4, 2015, Pages F349-F357

  Ravichandran, Kameswaran ^a   Ozkok, Abdullah ^a   Wang, Qian ^a   Mullick, Adam E ^b   Edelstein, Charles L ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b ISIS PHARMACEUTICALS   (United States)

Author keywords

Angiotensinogen; Cytokines; Fibrosis; Polycystic kidney; Polycystic kidney disease; Renin angiotensin system

Indexed keywords

ANGIOTENSINOGEN; ANGIOTENSINOGEN ANTISENSE OLIGONUCLEOTIDE; ANTISENSE OLIGONUCLEOTIDE; CXCL1 CHEMOKINE; CYTOKINE; INTERLEUKIN 12; MESSENGER RNA; RENIN; SCAVENGER RECEPTOR; SCAVENGER RECEPTOR ANTISENSE OLIGONUCLEOTIDE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; UREA; AGT PROTEIN, MOUSE; CD36 ANTIGEN; CXCL1 PROTEIN, MOUSE; POLYCYSTIC KIDNEY DISEASE 2 PROTEIN; POLYCYSTIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTISENSE THERAPY; ARTICLE; BODY WEIGHT; CHRONIC DISEASE; CONTROLLED STUDY; GENE MUTATION; IMMUNE SYSTEM; IMMUNOASSAY; IMMUNOHISTOCHEMISTRY; INFLAMMATION; KIDNEY CYST; KIDNEY FIBROSIS; KIDNEY FUNCTION; KIDNEY MASS; KIDNEY POLYCYSTIC DISEASE; KIDNEY SIZE; MOLECULE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UREA NITROGEN BLOOD LEVEL; ANIMAL; C57BL MOUSE; CELL CULTURE; CONVALESCENCE; DISEASE MODEL; DOWN REGULATION; FEMALE; FIBROSIS; GENE THERAPY; GENETICS; KIDNEY; MALE; METABOLISM; MUTANT MOUSE STRAIN; MUTATION; PATHOLOGY; PATHOPHYSIOLOGY; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; PROCEDURES;

ANGIOTENSINOGEN; ANIMALS; ANTIGENS, CD36; BLOOD UREA NITROGEN; CELLS, CULTURED; CHEMOKINE CXCL1; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; FIBROSIS; GENETIC THERAPY; INTERLEUKIN-12; KIDNEY; MALE; MICE, INBRED C57BL; MICE, MUTANT STRAINS; MUTATION; OLIGONUCLEOTIDES, ANTISENSE; POLYCYSTIC KIDNEY, AUTOSOMAL DOMINANT; RECOVERY OF FUNCTION; RNA, MESSENGER; TRANSFORMING GROWTH FACTOR BETA; TRPP CATION CHANNELS;

EID: 84922924416     PISSN: 1931857X     EISSN: 15221466     Source Type: Journal    
DOI: 10.1152/ajprenal.00478.2014     Document Type: Article

References (56)

1. Amura CR, Brodsky KS, Gitomer B, McFann K, Lazennec G, Nichols MT, Jani A, Schrier RW, Doctor RB. CXCR2 agonists in ADPKD liver cyst fluids promote cell proliferation. Am J Physiol Cell Physiol 294: C786-C796, 2008.
2. Amura CR, Brodsky KS, Groff R, Gattone VH, Voelkel NF, Doctor RB. VEGF receptor inhibition blocks liver cyst growth in pkd2(WS25/—) mice. Am J Physiol Cell Physiol 293: C419-C428, 2007.
3. Bhunia AK, Piontek K, Boletta A, Liu L, Qian F, Xu PN, Germino FJ, Germino GG. PKD1 induces p21(waf1) and regulation of the cell cycle via direct activation of the JAK-STAT signaling pathway in a process requiring PKD2. Cell 109: 157-168, 2002.
4. Cao W, Xu J, Zhou ZM, Wang GB, Hou FF, Nie J. Advanced oxidation protein products activate intrarenal renin-angiotensin system via a CD36-mediated, redox-dependent pathway. Antioxid Redox Signal 18: 19-35, 2013.
5. Carney EF. Polycystic kidney disease: TGF-ß signalling and vascular complications in ADPKD. Nat Rev Nephrol 9: 694, 2013.
6. Chapman AB, Johnson A, Gabow PA, Schrier RW. The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease. N Engl J Med 323: 1091-1096, 1990.
7. Chapman AB, Torres VE, Perrone RD, Steinman TI, Bae KT, Miller JP, Miskulin DC, Rahbari OF, Masoumi A, Hogan MC, Winklhofer FT, Braun W, Thompson PA, Meyers CM, Kelleher C, Schrier RW. The HALT polycystic kidney disease trials: design and implementation. Clin J Am Soc Nephrol 5: 102-109, 2010.
8. Cowley BD Jr, Rupp JC, Muessel MJ, Gattone VH. Gender and the effect of gonadal hormones on the progression of inherited polycystic kidney disease in rats. Am J Kidney Dis 29: 265-272, 1997.
9. Davisson RL, Kim HS, Krege JH, Lager DJ, Smithies O, Sigmund CD. Complementation of reduced survival, hypotension, and renal abnormalities in angiotensinogen-deficient mice by the human renin and human angiotensinogen genes. J Clin Invest 99: 1258-1264, 1997.
10. Decleves AE, Sharma K. Novel targets of antifibrotic and anti-inflammatory treatment in CKD. Nat Rev Nephrol 10: 257–267, 2014.
11. Del VM, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini A. Interleukin-12: biological properties and clinical application. Clin Cancer Res 13: 4677-4685, 2007.
12. Dell KM, Nemo R, Sweeney WE Jr, Levin JI, Frost P, Avner ED. A novel inhibitor of tumor necrosis factor-alpha converting enzyme ameliorates polycystic kidney disease. Kidney Int 60: 1240-1248, 2001.
13. Doctor RB, Serkova N, Hasebroock K, Zafar I, Edelstein CL. Distinct patterns of kidney and liver cyst growth in Pkd2WS25/— mice. Nephrol Dial Transplant 25: 3496-3504, 2010.
14. Duffield JS. Cellular and molecular mechanisms in kidney fibrosis. J Clin Invest 124: 2299-2306, 2014.
15. Edelstein CL. What is the role of tubular epithelial cell apoptosis in polycystic kidney disease (PKD)? Cell Cycle 4: e141-e145, 2005.
16. Elberg D, Jayaraman S, Turman MA, Elberg G. Transforming growth factor-beta inhibits cystogenesis in human autosomal dominant polycystic kidney epithelial cells. Exp Cell Res 318: 1508-1516, 2012.
17. Farris AB, Adams CD, Brousaides N, Della Pelle PA, Collins AB, Moradi E, Smith RN, Grimm PC, Colvin RB. Morphometric and visual evaluation of fibrosis in renal biopsies. J Am Soc Nephrol 22: 176-186, 2011.
18. Faubel S, Lewis EC, Reznikov L, Ljubanovic D, Hoke TS, Somerset H, Oh DJ, Lu L, Klein CL, Dinarello CA, Edelstein CL. Cisplatin-induced ARF is associated with an increase in the cytokines IL-1ß, IL-18, IL-6 and neutrophil infiltration in the kidney. J Pharmacol Exp Ther 322: 8-15, 2007.
19. Gee K, Guzzo C, Che Mat NF, Ma W, Kumar A. The IL-12 family of cytokines in infection, inflammation and autoimmune disorders. Inflamm Allergy Drug Targets 8: 40-52, 2009.
20. Grantham JJ. 1992 Homer Smith Award. Fluid secretion, cellular proliferation, and the pathogenesis of renal epithelial cysts. J Am Soc Nephrol 3: 1841-1857, 1993.
21. Grantham JJ, Mulamalla S, Swenson-Fields KI. Why kidneys fail in autosomal dominant polycystic kidney disease. Nat Rev Nephrol 7: 556-566, 2011.
22. Hassane S, Leonhard WN, van der Wal A, Hawinkels LJ, Lantinga-van Leeuwen IS, ten DP, Breuning MH, de Heer E, Peters DJ. Elevated TGFß-Smad signalling in experimental Pkd1 models and human patients with polycystic kidney disease. J Pathol 222: 21-31, 2010.
23. Hsieh CS, Macatonia SE, Tripp CS, Wolf SF, O’Garra A, Murphy KM. Development of TH1 CD4+ T cells through IL-12 produced by Listeria-induced macrophages. Science 260: 547-549, 1993.
24. Karihaloo A, Koraishy F, Huen SC, Lee Y, Merrick D, Caplan MJ, Somlo S, Cantley LG. Macrophages promote cyst growth in polycystic kidney disease. J Am Soc Nephrol 22: 1809-1814, 2011.
25. Keith DS, Torres VE, Johnson CM, Holley KE. Effect of sodium chloride, enalapril, and losartan on the development of polycystic kidney disease in Han:SPRD rats. Am J Kidney Dis 24: 491–498, 1994.
26. Kordasiewicz HB, Stanek LM, Wancewicz EV, Mazur C, McAlonis MM, Pytel KA, Artates JW, Weiss A, Cheng SH, Shihabuddin LS, Hung G, Bennett CF, Cleveland DW. Sustained therapeutic reversal of Huntington’s disease by transient repression of huntingtin synthesis. Neuron 74: 1031-1044, 2012.
27. Li X, Magenheimer BS, Xia S, Johnson T, Wallace DP, Calvet JP, Li R. A tumor necrosis factor-a-mediated pathway promoting autosomal dominant polycystic kidney disease. Nat Med 14: 863-868, 2008.
28. Liu D, Wang CJ, Judge DP, Halushka MK, Ni J, Habashi JP, Moslehi J, Bedja D, Gabrielson KL, Xu H, Qian F, Huso D, Dietz HC, Germino GG, Watnick T. A Pkd1-Fbn1 genetic interaction implicates TGF-ß signaling in the pathogenesis of vascular complications in autosomal dominant polycystic kidney disease. J Am Soc Nephrol 25: 81-91, 2014.
29. Liu Y, Dai B, Xu C, Fu L, Hua Z, Mei C. Rosiglitazone inhibits transforming growth factor-ß1 mediated fibrogenesis in ADPKD cyst-lining epithelial cells. PLos One 6: e28915, 2011.
30. Loghman-Adham M, Soto CE, Inagami T, Cassis L. The intrarenal renin-angiotensin system in autosomal dominant polycystic kidney disease. Am J Physiol Renal Physiol 287: F775-F788, 2004.
31. Long DA, Price KL, Herrera-Acosta J, Johnson RJ. How does angiotensin II cause renal injury? Hypertension 43: 722-723, 2004.
32. Makino N, Sugano M, Ohtsuka S, Sawada S. Intravenous injection with antisense oligodeoxynucleotides against angiotensinogen decreases blood pressure in spontaneously hypertensive rats. Hypertension 31: 1166-1170, 1998.
33. Melnikov VY, Faubel SG, Siegmund B, Lucia MS, Ljubanovic D, Edelstein CL. Neutrophil-independent mechanisms of caspase-1- and IL-18-mediated ischemic acute tubular necrosis in mice. J Clin Invest 110: 1083-1091, 2002.
34. Ogborn MR, Sareen S, Pinette G. Cilazapril delays progression of hypertension and uremia in rat polycystic kidney disease. Am J Kidney Dis 26: 942-946, 1995.
35. Raizada V, Skipper B, Luo W, Griffith J. Intracardiac and intrarenal renin-angiotensin systems: mechanisms of cardiovascular and renal effects. J Investig Med 55: 341-359, 2007.
36. Ravichandran K, Edelstein CL. Polycystic kidney disease: a case of suppressed autophagy? Semin Nephrol 34: 27-33, 2014.
37. Ravichandran K, Zafar I, He Z, Doctor RB, Moldovan R, Mullick AE, Edelstein CL. An mTOR anti-sense oligonucleotide decreases polycystic kidney disease in mice with a targeted mutation in Pkd2. Hum Mol Genet 23: 4919-4931, 2014.
38. Ruiz-Ortega M, Ruperez M, Esteban V, Rodriguez-Vita J, Sanchez-Lopez E, Carvajal G, Egido J. Angiotensin II: a key factor in the inflammatory and fibrotic response in kidney diseases. Nephrol Dial Transplant 21: 16-20, 2006.
39. Schaffner DL, Barrios R, Massey C, Banez EI, Ou CN, Rajagopalan S, Aguilar-Cordova E, Lebovitz RM, Overbeek PA, Lieberman MW.Targeting of the rasT24 oncogene to the proximal convoluted tubules in transgenic mice results in hyperplasia and polycystic kidneys. Am J Pathol 142: 1051-1060, 1993.
40. Schrier RW. Renal volume, renin-angiotensin-aldosterone system, hypertension, and left ventricular hypertrophy in patients with autosomal dominant polycystic kidney disease. J Am Soc Nephrol 20: 1888-1893, 2009.
41. Sharma N, Malarkey EB, Berbari NF, O’Connor AK, Vanden Heuvel GB, Mrug M, Yoder BK. Proximal tubule proliferation is insufficient to induce rapid cyst formation after cilia disruption. J Am Soc Nephrol 24: 456–464, 2013.
42. Sparks MA, Crowley SD, Gurley SB, Mirotsou M, Coffman TM. Classical renin-angiotensin system in kidney physiology. Compr Physiol 4: 1201-1228, 2014.
43. Talbot JJ, Shillingford JM, Vasanth S, Doerr N, Mukherjee S, Kinter MT, Watnick T, Weimbs T. Polycystin-1 regulates STAT activity by a dual mechanism. Proc Natl Acad Sci USA 108: 7985-7990, 2011.
44. Theuer J, Dechend R, Muller DN, Park JK, Fiebeler A, Barta P, Ganten D, Haller H, Dietz R, Luft FC. Angiotensin II induced inflammation in the kidney and in the heart of double transgenic rats. BMC Cardiovasc Disord 2: 3, 2002.
45. Thomson RB, Mentone S, Kim R, Earle K, Delpire E, Somlo S, Aronson PS. Histopathological analysis of renal cystic epithelia in the Pkd2WS25/— mouse model of ADPKD. Am J Physiol Renal Physiol 285: F870-F880, 2003.
46. Torres VE, Donovan KA, Scicli G, Holley KE, Thibodeau SN, Car-retero OA, Inagami T, McAteer JA, Johnson CM. Synthesis of renin by tubulocystic epithelium in autosomal-dominant polycystic kidney disease. Kidney Int 42: 364–373, 1992.
47. Torres VE, Wang X, Qian Q, Somlo S, Harris PC, Gattone VH. Effective treatment of an orthologous model of autosomal dominant polycystic kidney disease. Nat Med 10: 363–364, 2004.
48. Tripp CS, Wolf SF, Unanue ER. Interleukin 12 and tumor necrosis factor alpha are costimulators of interferon gamma production by natural killer cells in severe combined immunodeficiency mice with listeriosis, and interleukin 10 is a physiologic antagonist. Proc Natl Acad Sci USA 90: 3725–3729, 1993.
49. Trudel M, D’Agati V, Costantini F. C-myc as an inducer of polycystic kidney disease in transgenic mice. Kidney Int 39: 665–671, 1991.
50. Wei W, Popov V, Walocha JA, Wen J, Bello-Reuss E. Evidence of angiogenesis and microvascular regression in autosomal-dominant poly-cystic kidney disease kidneys: a corrosion cast study. Kidney Int 70: 1261–1268, 2006.
51. Weimbs T, Olsan EE, Talbot JJ. Regulation of STATs by polycystin-1 and their role in polycystic kidney disease. JAKSTAT 2: e23650, 2013.
52. Wilson PD. Polycystic kidney disease. N Engl J Med 350: 151–164, 2004.
53. Wu C, Lu H, Cassis LA, Daugherty A. Molecular and pathophysiolog-ical features of angiotensinogen: a mini review. N Am J Med Sci (Boston) 4: 183–190, 2011.
54. Wu G, D’Agati V, Cai Y, Markowitz G, Park JH, Reynolds DM, Maeda Y, Le TC, Hou H Jr, Kucherlapati R, Edelmann W, Somlo S. Somatic inactivation of Pkd2 results in polycystic kidney disease. Cell 93: 177–188, 1998.
55. Zafar I, Tao Y, Falk S, McFann K, Schrier RW, Edelstein CL. Effect of statin and angiotensin-converting enzyme inhibition on structural and hemodynamic alterations in autosomal dominant polycystic kidney disease model. Am J Physiol Renal Physiol 293: F854–F859, 2007.
56. Zeier M, Pohlmeyer G, Deerberg F, Schonherr R, Ritz E. Progression of renal failure in the Han: SPRD polycystic kidney rat. Nephrol Dial Transplant 9: 1734–1739, 1994.